In the RAS G12-mutated population, daraxonrasib significantly improved median OS (13.2 vs 6.6 months) and median PFS (7.3 vs 3.5 months) compared with chemotherapy. The Food and Drug Administration ...
Cancer progression within 36 months of combination therapy identified patients with overall survival of less than 2 years.
Jideytro is FDA-approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC who received prior ROS1 TKI therapy.
Retatrutide 12mg achieved up to 22.6% (55.8 lbs) mean weight loss at week 80, alongside marked improvements in ...
In a scientific statement, the association states that consuming caffeinated coffee linked to reduced risks for type 2 diabetes, heart disease, stroke, heart failure.
Credit: mannKind. Furoscix ReadyFlow offers a rapid, outpatient alternative for acute fluid overload management in heart failure and chronic kidney disease. Furoscix ReadyFlow demonstrated a ...
The analysis included 75 brick-and-mortar weight-loss clinics and medical spas offering compounded GLP-1 RAs. HealthDay News — Despite the end of nationwide shortages of glucagon-like peptide-1 ...
One in about 7300 individuals in the general population have PMS, a rare genetic condition that causes medical, intellectual, and behavioral challenges.
Lundbeck’s investigational oral orexin 2 receptor agonist gains Fast Track status, aiming to address underlying pathophysiology in patients with narcolepsy.
TG-C is a novel, off-the-shelf cell and gene therapy designed to slow OA progression and provide a non-surgical alternative to standard of care therapies.
Delaying JAK inhibitor initiation yielded higher early antibody responses; earlier initiation linked to earlier improvement in arthritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results